United States· US:71205-858_ffd82a69-a64c-4399-8f5d-bddc70cdc3cf
Cyclobenzaprine Hydrochloride
A cyclobenzaprine product containing cyclobenzaprine hydrochloride, registered in United States by Proficient Rx LP. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Cyclobenzaprine is registered in 3 of 19 countries.
Countries holding a registration under ATC M03BX08 (cyclobenzaprine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Cyclobenzaprine · ATC M03BX08
3 / 19 countries
- Canada
- Norwayprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CYCLOBENZAPRINE HYDROCHLORIDE
- Manufacturer
- Proficient Rx LP
- Country
- United States (US)
- ATC code
- M03BX08
- ATC class
- Cyclobenzaprine
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 14
- ndc117120585800100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-00)
- ndc1171205858111000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-11)
- ndc11712058583030 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-30)
- ndc117120585855500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-55)
- ndc11712058586060 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-60)
- ndc117120585872120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-72)
- ndc11712058589090 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71205-858-90)
- ndc1171205-858-00
- ndc1171205-858-11
- ndc1171205-858-30
- ndc1171205-858-55
- ndc1171205-858-60
- ndc1171205-858-72
- ndc1171205-858-90
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
319 interactions on record for cyclobenzaprine.
Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cyclobenzaprine · interactions on record
319 records
- 20 severe
- 113 moderate
- 1 minor
- 185 info
Most severe, free to view
- FenfluramineA08AA02severe
- DexfenfluramineA08AA04severe
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cyclobenzaprine in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaAG-CYCLOBENZAPRINEANGITA PHARMA INC.
- SpainYURELAX 10 mg CAPSULAS DURASViatris Healthcare Limited
- NorwayCyclobenzaprine HCl solcoSolco
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Spain · Yurelax
- Italy · Flexiban
- Portugal · Flexiban, Miodia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fa2e60aa-89ee-4781-bd1c-94720aab9378 GET /v1/drugs/fa2e60aa-89ee-4781-bd1c-94720aab9378?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "30",
"substance": "CYCLOBENZAPRINE HYDROCHLORIDE",
"productndc": "71205-858",
"dosage_form": "CAPSULE, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA091281",
"marketing_category": "ANDA"
}See everything about cyclobenzaprine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.